The long-term consequences of methamphetamine (METH) abuse include a persistent, partial loss of monoamine systems in the brain, particularly the dopamine (DA) innervation of the striatum. Several events post-synaptic to DA terminals and occurring shortly (within ~ 8 hr) after administration of a neurotoxic regimen of METH are implicated in this neurotoxicity. However, the nature of the relationship between these post-synaptic events and the neurotoxic consequences of that treatment on the DA nerve terminal is less clear. One factor that has been implicated in this neurotoxicity is the production of nitric oxide (NO). Although it is relatively clear that NO contributes to METH-induced neurotoxicity to the DA nerve terminal, the source of this NO has not been clearly delineated. Evidence suggests that the generation of NO arises as a consequence of the activation of neuronal nitric oxide synthase (nNOS) located post-synaptic to the DA nerve terminal, in a subpopulation of striatal interneurons. Interestingly, it has been shown that rats with partial DA loss induced by high doses of METH do not exhibit further striatal DA loss when later re-exposed to a second neurotoxic regimen of METH. Thus, it appears that animals with partial striatal DA depletion are resistant to further METH-induced neurotoxicity. Preliminary evidence suggests that nNOS activation in striatal interneurons is increased 1 hour after a neurotoxic regimen of METH, but not in animals who received a prior neurotoxic regimen of METH (i.e. those animals with a partial DA depletion). Furthermore, it has been shown that partial DA loss is associated with altered function of the DA D1 receptor-containing striatonigral efferent neurons. In light of these observations, the overall hypothesis of this project is that DA-mediated activation of the nNOS- containing striatal interneurons is necessary for METH-induced neurotoxicity.
Three specific aims are proposed to test this hypothesis by 1) determining whether inhibiting activation of nNOS-containing interneurons in the striatum blocks METH-induced neurotoxicity;2) determining whether targeted knockdown of nNOS expression in the striatum blocks METH-induced neurotoxicity;and 3) determining whether prior DA depletion blocks subsequent METH-induced neurotoxicity. Completion of these experiments will provide novel insight into the role of DA signaling and nNOS-containing striatal interneurons in METH-induced neurotoxicity. Information gained as a result of these studies would allow for the development of targeted interventions to address the neurotoxic potential of METH.

Public Health Relevance

Approximately 12 million Americans age 12 and older have tried methamphetamine (METH). It is now established that METH abuse leads to long-lasting decreases in the dopamine (DA) innervation of the caudate-putamen in humans, as well as other species. The goal of this project is to determine the underlying causes of this neurotoxicity and to examine the role of DA signaling and neuronal nitric oxide synthase (nNOS)-containing striatal interneurons in this neurotoxicity.

National Institute of Health (NIH)
National Institute on Drug Abuse (NIDA)
Postdoctoral Individual National Research Service Award (F32)
Project #
Application #
Study Section
Special Emphasis Panel (ZRG1-F02A-J (20))
Program Officer
Babecki, Beth
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of Utah
Schools of Pharmacy
Salt Lake City
United States
Zip Code
Fricks-Gleason, Ashley N; German, Christopher L; Hoonakker, Amanda J et al. (2016) An acute, epitope-specific modification in the dopamine transporter associated with methamphetamine-induced neurotoxicity. Synapse 70:139-46
Fricks-Gleason, Ashley N; Keefe, Kristen A (2013) Evaluating the role of neuronal nitric oxide synthase-containing striatal interneurons in methamphetamine-induced dopamine neurotoxicity. Neurotox Res 24:288-97
Friend, Danielle M; Son, Jong H; Keefe, Kristen A et al. (2013) Expression and activity of nitric oxide synthase isoforms in methamphetamine-induced striatal dopamine toxicity. J Pharmacol Exp Ther 344:511-21